 this is a transcript of the fourth quarter and year end 2022 financial and business update call for Acorda Therapeutics. 
 this is a transcript of the fourth quarter and full year 2022 financial and business update for Acorda Therapeutics, which was held on march 9, 2023. 
 we ended the year with net sales of $19 million, a 13.1% decrease over the fourth quarter of 2021 and a 146% increase over the first quarter of 2022. 
 net sales for the full year 2022 were $73 million, a 13.7% decrease from 2021. in addition to our net sales, we reported $2.9 million of INBRIJA ex-U.S. sales, $11.7 million of FAMPYRA royalties, $2.6 million in royalties for Neurelis and $500,000 from Asieris Pharma for the clinical assets we licensed to them. 
 we expect to be cash flow neutral to positive in 2023 and we expect our ending cash balance to be between $43 million and $47 million.    
 # 1#2#3#4#1 * # 2 *, # 3 ( # 4 ) # 1#2#3#4#5#6#7    # 1*#1 *, # 2 ( # 4 ) # 3 ( # 4 ) # 5#6#7    # 1 * # 1 *, # 2 ( # 5 ) # 3 ( # 4 ) # 10#1 * # 1 *, # 2 ( # 4 ) # 11#1 * # 2 *, # 11#1 * # 1 *, # 2 *, # 3 ( # 10 ) # 1 *, # 2 ( # 11 ) # 1 *, # 2 ( # 12 ) # 1 *, # 2 ( # 13 ) # 1 *, # 2 ( # 14 ) # 1 *, # 2 ( # 15 ) # 1 *, # 2 ( # 16 ) # 1 *, # 2 ( # 17 ) # 1 *, # 2 ( # 18 ) # 1 *, # 19 ( # 19 ) # 1 *, #